Sep 2026· International Journal of Molecular Sciences· Vol 27, pp. 7859· 0 citations· 235 references
Medicine
TL;DR
This review provides a comprehensive synthesis of DAMP biology in mesothelioma, highlighting the emerging therapeutic opportunities targeting DAMP-associated pathways.
Abstract
Mesothelioma is a rare and aggressive malignancy arising from mesothelial cells. Despite recent advances in systemic therapies, overall survival remains limited, underscoring the need for a deeper mechanistic understanding of disease pathogenesis and novel therapeutic strategies. In mesothelioma, chronic tissue injury induced by asbestos fibers leads to sustained activation of innate immune pathways and chronic inflammation that actively promote tumorigenesis. The release of Damage-Associated Molecular Patterns (DAMPs)—endogenous molecules that signal cellular stress and damage—contributes to establishing a self-sustaining inflammatory circuit within the pleural microenvironment that promotes tumor initiation and progression and immune evasion. Among DAMPs, High-Mobility Group Box 1 (HMGB1) has emerged as a key regulator of mesothelioma pathogenesis. Several studies demonstrated that mesothelial cells actively secrete HMGB1 in response to asbestos exposure, driving macrophage recruitment, cytokine production, and chronic inflammation. Beyond HMGB1, additional DAMPs—including IL-33, extracellular ATP, cell-free nucleic acids, heat shock proteins, and calreticulin—contribute to inflammasome activation, stromal remodeling, and immune dysregulation. Recent evidence suggests that DAMP signaling in mesothelioma is dysregulated, resulting in chronic inflammation coupled with ineffective antitumor immunity. This review provides a comprehensive synthesis of DAMP biology in mesothelioma, highlighting the emerging therapeutic opportunities targeting DAMP-associated pathways.
Pleural mesothelioma (PM) is a rare and aggressive cancer with limited treatment options and poor prognosis. Unlike other thoracic cancers responding well to immunotherapy, PM typically lacks key predictive biomarkers such as Programmed Death-Ligand 1 (PD-L1) tumor expression. Nonetheless, immune checkpoint inhibitors...
L. Cerbone, Alessia Garau, Andrea Balossino et al.· Frontiers in Immunology· 0 citations
Neutrophil extracellular traps (NETs) are extracellular networks of decondensed chromatin and granular proteins generated by neutrophils in response to activating stimuli. Growing evidence indicates that NETs participate in colorectal cancer (CRC) development through their interactions with chronic inflammation, immune...
Yuan-Sha Ge, Wei-Jia Kong, Y. Qian et al.· Frontiers in Immunology· 0 citations
Although antibiotic therapy effectively cures active tuberculosis (TB), many survivors are left with permanent lung damage and long-lasting immune alterations. Growing epidemiological evidence indicates that individuals with prior pulmonary TB have a two- to three-fold increased risk of lung cancer, independent of smok...
Praise Audax Rukonge, Vincent Kawuribi, Zhi-Meng Lu et al.· Frontiers in Immunology· 0 citations
Cancer remains a critical global health concern due to late detection, drug resistance, and high mortality. Mesothelin (MSLN) is a glycoprotein highly expressed on the surface of various cancer cells, including those of ovarian, pancreatic, and gastric cancers. Thus, it could be a valuable target for both as a biomarke...
Manoj-Kumar Gupta, Ramakrishna Vadde, G. Nagaraju· MedComm· 0 citations
Tumor drug resistance is still the core obstacle limiting the long-term benefit of modern anticancer therapy, especially in the context of treatment tolerance, persistence of minimal residual disease (MRD) and recurrence after treatment. Increasing evidence has shown that therapy-associated myeloid niches can involve c...
Ting Li, Yan-Xia Lin, Q. Gang et al.· Cancer Letters· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.